Moderate–severe tricuspid regurgitation reduced likelihood of ≥50% target dose up-titration of RASi/ARNi (OR=0.572) and beta-blockers (OR=0.526) in HFrEF patients.
Does moderate-severe tricuspid regurgitation reduce the likelihood of guideline-directed medical therapy optimization in patients with acute decompensated heart failure and reduced ejection fraction?
Moderate-severe tricuspid regurgitation is a significant barrier to the up-titration of RASi/ARNi and beta-blockers in patients with HFrEF following an acute decompensation, though those who do achieve optimization still derive mortality benefits.
Absolute Event Rate: 0% vs 0%
Abstract Background Guideline-directed medical therapy (GDMT) reduces mortality in heart failure with reduced ejection fraction (HFrEF), but multiple barriers prevent the correct implementation of recommended treatments. Aims We sought to evaluate the role of tricuspid regurgitation (TR) as an obstacle for GDMT implementation in a cohort of HFrEF patients after an episode of acute decompensated heart failure (ADHF). Methods We enrolled patients hospitalized for ADHF with left ventricular ejection fraction (LVEF) ≤ 40%. TR severity was categorized as moderate–severe or trivial-mild. Optimization of renin–angiotensin system inhibitors/angiotensin receptor-neprilysin inhibitors (RASi/ARNi), beta-blockers and mineralocorticoid receptor antagonists (MRA) therapy was defined when patients were prescribed these drugs at ≥50% of the target dose (TD) at 1-year follow-up. Results 858 patients were enrolled. At 12 months, patients receiving ≥50% TD of RASi/ARNi, beta-blockers and MRA were 51%, 29%, and 47% respectively. After adjustment for multiple confounders, moderate–severe TR was inversely associated with the likelihood of ≥50% TD up-titration of RASi/ARNi (OR = 0.572, P = .029) and of beta-blockers (OR = 0.526, P = .038), but not of MRA (OR = 0.995, P = .984). RASi/ARNi and beta-blockers optimization was associated with lower 1- and 5-years all-cause mortality risk regardless the severity of TR. The association between RASi/ARNi optimization and 5-years survival was more pronounced in patients with moderate–severe TR vs patients with trivial-mild TR (P for int = .039). Conclusions The severity of TR in ADHF is a determinant of poor implementation of RASi/ARNi and beta-blockers therapy at 1-year follow-up; however, the lower mortality associated with treatment optimization was not influenced by TR severity.
Brollo et al. (Thu,) reported a other. Moderate–severe tricuspid regurgitation reduced likelihood of ≥50% target dose up-titration of RASi/ARNi (OR=0.572) and beta-blockers (OR=0.526) in HFrEF patients.